secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-04-24T23:59:59+00:00
Accession:  0000950170-24-047567
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q1 net loss $27.4M; VK2735 obesity drug shows up to 14.7% weight loss; cash $963M
--------------------------------------------------------------------------------

- Q1 net loss $27.4M ($0.26/sh), R&D expense $24.1M, G&A $10.0M.
- Phase 2 VENTURE: VK2735 hit primary endpoint; up to 14.7% weight loss from baseline, 13.1% placebo-adjusted at 13 weeks.
- Phase 1 oral VK2735: up to 5.3% weight loss from baseline (3.3% placebo-adjusted) at 28 days; no SAEs; plan Phase 2 in obesity later 2024.
- Phase 2b VOYAGE (VK2809 in NASH/fibrosis) 52-week histology data expected in 2Q24.
- Q1 gross proceeds $632.5M from stock offering; cash & investments $963M as of Mar 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/0000950170-24-047567-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024047567/vktx-20240424.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-047567

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer